Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

Abstract Background CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor. This Phase IIa study assessed the effects of CHF6001 on markers of inflammation in induced sputum and blood in patients with chronic obstructive pulmonary disease (COPD). Methods This was a multicentre, three-period (each...

Full description

Bibliographic Details
Main Authors: Dave Singh, Kai Michael Beeh, Brendan Colgan, Oliver Kornmann, Brian Leaker, Henrik Watz, Germano Lucci, Silvia Geraci, Aida Emirova, Mirco Govoni, Marie Anna Nandeuil
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Respiratory Research
Subjects:
Induced sputum
Inflammation
Phosphodiesterase 4 inhibitors
Pharmacology
Chronic obstructive pulmonary disease
Online Access:http://link.springer.com/article/10.1186/s12931-019-1142-7

Internet

http://link.springer.com/article/10.1186/s12931-019-1142-7

Similar Items